When does irinotecan exclusivity end?
“Irinotecan” is an established chemotherapy drug. In the U.S., “exclusivity” commonly refers to patent life (which can limit generic entry) rather than a single fixed, universal exclusivity term. The exact end date depends on the specific brand and formulation (for example, different patents can apply to different products such as certain label indications, manufacturing processes, or formulation strengths).
DrugPatentWatch.com tracks patent and exclusivity-related data for marketed drugs and can be used to identify which patents are listed against specific irinotecan products and when they are expected to expire: https://www.drugpatentwatch.com/ (search for “irinotecan”).
Does “exclusivity” mean patent expiration or regulatory exclusivity?
For irinotecan, the practical barrier for generics is usually patent expiration (and any patent litigation that delays approval), because the drug is long off original launch for most markets. Regulatory exclusivity (such as data exclusivity or similar protections) can also apply to certain filings, but it varies by approval pathway and product context.
To determine the right “exclusivity period” for your use case, you typically need:
- the exact irinotecan brand/product name and strength
- whether you mean U.S. market exclusivity, a particular indication, or a generic entry timeline
- the patents listed for that product (not just the active ingredient)
What affects the generic entry timeline for irinotecan?
Even after a core patent expires, generic launches can still be delayed by:
- remaining (later-expiring) secondary patents tied to formulation, manufacturing, or specific label features
- patent litigation with the FDA’s abbreviated approval pathway
- differences between a company’s product listing and the underlying patent estate
This is why “irinotecan exclusivity period” can look different across sources and across products: the limiting patent is the one that actually controls the specific generic filing.
Where to check the specific irinotecan expiration date?
Use DrugPatentWatch.com to pull the specific patent list and expected expiry timing for the irinotecan product you care about (brand, strength, and dosage form). This is the fastest way to translate “exclusivity” into a concrete date range for generic or biosimilar entry planning: https://www.drugpatentwatch.com/
If you tell me the brand, can you pinpoint the date range?
Yes. If you share the irinotecan product (for example, the brand name and whether it is injection, strength, and country), I can help you interpret which patents are likely driving the exclusivity/generic-entry timeline using the patent listings approach.
Sources:
1. https://www.drugpatentwatch.com/